Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Non-Current Liabilities (2016 - 2020)

Niagen Bioscience (NAGE) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $250000.0 as the latest value for Q2 2020.

  • On a quarterly basis, Other Non-Current Liabilities fell 14.68% to $250000.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $250000.0, a 14.68% decrease, with the full-year FY2019 number at $169000.0, down 38.55% from a year prior.
  • Other Non-Current Liabilities was $250000.0 for Q2 2020 at Niagen Bioscience, up from $238000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $503850.0 in Q3 2017 to a low of $155000.0 in Q3 2018.
  • A 5-year average of $286329.8 and a median of $275000.0 in 2018 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 63.28% in 2018, then skyrocketed 79.7% in 2019.
  • Niagen Bioscience's Other Non-Current Liabilities stood at $389010.0 in 2016, then fell by 19.28% to $314000.0 in 2017, then fell by 12.42% to $275000.0 in 2018, then plummeted by 38.55% to $169000.0 in 2019, then soared by 47.93% to $250000.0 in 2020.
  • Per Business Quant, the three most recent readings for NAGE's Other Non-Current Liabilities are $250000.0 (Q2 2020), $238000.0 (Q1 2020), and $169000.0 (Q4 2019).